Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGX Stock Forecast 2026-2027
$1.48
Current Price
$55.68M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MGX Price Targets
+710.8%
To High Target of $12.00
+508.1%
To Median Target of $9.00
+373.0%
To Low Target of $7.00
MGX Price Momentum
+5.7%
1 Week Change
+4.2%
1 Month Change
-2.6%
1 Year Change
-8.6%
Year-to-Date Change
-62.5%
From 52W High of $3.95
+18.4%
From 52W Low of $1.25
📊 TOP ANALYST CALLS
Did MGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Metagenomi is one of their latest high-conviction picks.
Latest MGX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, MGX has a bullish consensus with a median price target of $9.00 (ranging from $7.00 to $12.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $1.48, the median forecast implies a 508.1% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yanan Zhu at Wells Fargo, projecting a 710.8% upside. Conversely, the most conservative target is provided by Mitchell S. Kapoor at HC Wainwright & Co., suggesting a 373.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGX Analyst Ratings
4
Buy
1
Hold
0
Sell
MGX Price Target Range
Low
$7.00
Average
$9.00
High
$12.00
Current: $1.48
Latest MGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 19, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Reiterates | $7.00 |
| Aug 15, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $11.00 |
| Aug 14, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $12.00 |
| May 15, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $12.00 |
| May 14, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $16.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $7.00 |
| Mar 18, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $20.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $14.00 |
| Nov 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
| Nov 20, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $7.00 |
| Sep 5, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $7.00 |
| Aug 19, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Aug 15, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $17.00 |
| Jul 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $10.00 |
| May 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $10.00 |
| May 7, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $10.00 |
| May 2, 2024 | JP Morgan | Brian Cheng | Neutral | Downgrade | $6.00 |
Metagenomi, Inc. (MGX) Competitors
The following stocks are similar to Metagenomi based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Metagenomi, Inc. (MGX) Financial Data
Valuation Metrics
Market Cap
$55.68M
Enterprise Value
$-64,463,616
P/E Ratio
N/A
PEG Ratio
-0.9x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
-59.3%
Gross Margin
N/A
Operating Margin
-623.0%
Net Margin
0.0%
EPS Growth
-59.3%
Financial Health
Cash/Price Ratio
+288.8%
Current Ratio
7.2x
Debt/Equity
25.6x
ROE
-44.7%
ROA
-22.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Metagenomi, Inc. (MGX) Business Model
About Metagenomi, Inc.
What They Do
Develops advanced gene editing technologies.
Business Model
Metagenomi Inc. operates by utilizing its proprietary platform that leverages naturally occurring enzymes for precise genetic modifications. The company generates revenue through partnerships, licensing agreements, and collaborations across various sectors including healthcare, agriculture, and industrial biotechnology.
Additional Information
Metagenomi is positioned as a key player in the biotech industry, addressing significant challenges such as genetic disorders and crop resilience. The growing demand for innovative gene editing solutions enhances its market potential and relevance in developing therapies and sustainable practices.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
119
CEO
Dr. Jian Irish M.B.A., Ph.D.
Country
United States
IPO Year
2024
Website
metagenomi.coMetagenomi, Inc. (MGX) Latest News & Analysis
Latest News
Quick Summary
Metagenomi published research in Nature Structural & Molecular Biology on its proprietary compact CRISPR nuclease, which shows enhanced editing efficiency.
Why It Matters
Metagenomi's breakthrough in CRISPR technology could lead to advancements in gene editing, potentially boosting its market position and attracting investment in biotech innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
6 days ago
Quick Summary
Shareholders are advised to contact the firm promptly, as there may be a limited time to assert their rights, with legal fees handled on a contingent fee basis.
Why It Matters
The urgency for shareholders to act suggests potential legal issues or shareholder rights concerns, which could impact stock value and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) completed a pre-IND meeting for MGX-001, showing promising preclinical data. The company has $160.8M in cash, funding operations through Q4 2027.
Why It Matters
Positive preclinical data and upcoming regulatory submissions position Metagenomi for potential breakthroughs in gene therapy, while strong cash reserves ensure operational stability through 2027.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Metagenomi Therapeutics (MGX) reported a quarterly loss of $0.60 per share, slightly exceeding the Zacks Consensus Estimate of a loss of $0.58, improved from a loss of $0.63 per share a year prior.
Why It Matters
Metagenomi's larger-than-expected loss may signal ongoing financial challenges, potentially impacting investor confidence and stock performance. Year-over-year improvement could offer some reassurance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
1 month ago
Quick Summary
Metagenomi Therapeutics, Inc. (MGX) presented at the TD Cowen 46th Annual Health Care Conference, highlighting its developments and strategies in the biotech sector.
Why It Matters
Metagenomi's presentation may highlight advancements or partnerships that could impact its stock performance, growth potential, and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
1 month ago
Quick Summary
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) announced the appointment of Jian Irish, Ph.D., as part of its focus on developing curative genetic medicines.
Why It Matters
Metagenomi's announcement of a leadership change may indicate strategic shifts, impacting investor confidence and the company's future direction in the competitive genome editing sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MGX Stock
What is Metagenomi, Inc.'s (MGX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Metagenomi, Inc. (MGX) has a median price target of $9.00. The highest price target is $12.00 and the lowest is $7.00.
Is MGX stock a good investment in 2026?
According to current analyst ratings, MGX has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGX stock?
Wall Street analysts predict MGX stock could reach $9.00 in the next 12 months. This represents a 508.1% increase from the current price of $1.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Metagenomi, Inc.'s business model?
Metagenomi Inc. operates by utilizing its proprietary platform that leverages naturally occurring enzymes for precise genetic modifications. The company generates revenue through partnerships, licensing agreements, and collaborations across various sectors including healthcare, agriculture, and industrial biotechnology.
What is the highest forecasted price for MGX Metagenomi, Inc.?
The highest price target for MGX is $12.00 from Yanan Zhu at Wells Fargo, which represents a 710.8% increase from the current price of $1.48.
What is the lowest forecasted price for MGX Metagenomi, Inc.?
The lowest price target for MGX is $7.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 373.0% increase from the current price of $1.48.
What is the overall MGX consensus from analysts for Metagenomi, Inc.?
The overall analyst consensus for MGX is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are MGX stock price projections?
Stock price projections, including those for Metagenomi, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:21 AM UTC